Tural, D. Et Al. 2023. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice. Clinical Genitourinary Cancer , vol.21, no.3 , 334-341.

Tural, D., Arslan, C., Selcukbiricik, F., Olmez, O. F., Akar, E., ERMAN, M., ... ÜRÜN, Y.(2023). Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice. Clinical Genitourinary Cancer , vol.21, no.3, 334-341.

Tural, Deniz Et Al. "Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice," Clinical Genitourinary Cancer , vol.21, no.3, 334-341, 2023

Tural, Deniz Et Al. "Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice." Clinical Genitourinary Cancer , vol.21, no.3, pp.334-341, 2023

Tural, D. Et Al. (2023) . "Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice." Clinical Genitourinary Cancer , vol.21, no.3, pp.334-341.

@article{article, author={Deniz Tural Et Al. }, title={Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice}, journal={Clinical Genitourinary Cancer}, year=2023, pages={334-341} }